Home > Healthcare > Medical Devices > Implantable Devices > coronary artery bypass graft market
Get a free sample of Coronary Artery Bypass Graft Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Coronary Artery Bypass Graft Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The coronary artery bypass graft industry is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A key aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
Some of the eminent market participants operating in the coronary artery bypass graft industry include:
The traditional (on-pump) CABG segment dominated the market with a 55.1% revenue share in 2023, due to its established efficacy and widespread adoption in surgical practices.
The U.S. coronary artery bypass graft market surpassed USD 3.5 billion in 2023 and is expected to grow at a 6.7% CAGR through 2032, led by favorable reimbursement policies and advanced healthcare infrastructure.
The grafts segment was valued at over USD 3.1 billion in 2023, as these are essential components in CABG procedures.
The global market for coronary artery bypass graft was reached USD 11.8 billion in 2023 and is estimated to grow at a 7.1% CAGR from 2024 to 2032, driven by the increasing prevalence of cardiovascular diseases.
Key players in the industry include Abbott Laboratories, AngioDynamics, AtriCure, B. Braun Melsungen AG, Boston Scientific, Cardinal Health, CryoLife, Edwards Lifesciences, Johnson & Johnson, LivaNova, Medline Industries, Medtronic, Nipro Corporation, Stryker Corporation, and Terumo Corporation.